BioSpace News Archive

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer of Atara, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference.

Omnicell, Inc. (NASDAQ:OMCL), a leading provider of medication management solutions and adherence tools for healthcare systems and pharmacies, will release its financial results for the fourth quarter and full-year 2021, after market on Monday, February 14, 2022.

Kewaunee Scientific Corporation, a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, announced a change in its go-to-market channel strategy for the sale and distribution of its products.

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2022 on Wednesday, February 2, after the market closes.

OPKO Health, Inc. announced that management will be participating in the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10-13, 2022.

Rakuten Medical, Inc., a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox™, will present at the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10-13, 2022.

Cantabio Pharmaceuticals, Inc. announced that The Michael J. Fox Foundation for Parkinson’s Research has awarded the Company a major grant for a project entitled “Development of small-molecule inhibitors to reduce the aggregation of tau for the treatment of Parkinson’s disease.”

Vetigenics, an animal health biotechnology company, has announced preclinical data that paves the way for clinical evaluation of the first entirely canine, anti-CTLA4 antibody to promote anti-tumor immunity in dogs with immune-responsive cancers.

Carisma Therapeutics Inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, today announced that Steven Kelly, President and Chief Executive Officer of Carisma, will present at the 40th Annual J.P. Morgan Healthcare Conference.

Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the Curian® Campy assay has received U.S. Food and Drug Administration (FDA) clearance.